BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandborn WJ, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: Analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015;42:330-342. [PMID: 26031921 DOI: 10.1111/apt.13251] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Afzali A, Ciorba MA, Schwartz DA, Sharaf M, Fourment C, Ritter T, Wolf DC, Shafran I, Randall CW, Kane SV. Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned. Inflamm Bowel Dis 2017;24:2-4. [PMID: 29272481 DOI: 10.1093/ibd/izx015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 156] [Cited by in F6Publishing: 134] [Article Influence: 26.0] [Reference Citation Analysis]
4 Furfaro F, Fiorino G, Allocca M, Gilardi D, Danese S. Emerging therapeutic targets and strategies in Crohn's disease. Expert Rev Gastroenterol Hepatol 2016;10:735-44. [PMID: 26766496 DOI: 10.1586/17474124.2016.1142372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
6 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
7 Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis 2019;13:725-34. [PMID: 30753371 DOI: 10.1093/ecco-jcc/jjy223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
8 Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1453-68. [PMID: 32969507 DOI: 10.1111/apt.16096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
9 Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clinical Gastroenterology and Hepatology 2021;19:1209-1217.e2. [DOI: 10.1016/j.cgh.2020.04.078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ripollés T, Paredes JM, Martínez-Pérez MJ, Rimola J, Jauregui-Amezaga A, Bouzas R, Martin G, Moreno-Osset E. Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study. Inflamm Bowel Dis 2016;22:2465-73. [PMID: 27580385 DOI: 10.1097/MIB.0000000000000882] [Cited by in Crossref: 38] [Cited by in F6Publishing: 9] [Article Influence: 12.7] [Reference Citation Analysis]
11 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
12 Ding NS, Malietzis G, Lung PFC, Penez L, Yip WM, Gabe S, Jenkins JT, Hart A. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther 2017;46:883-91. [PMID: 28881017 DOI: 10.1111/apt.14293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
13 Lichtenstein GR, Mcgovern DPB. Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. Am J Gastroenterol Suppl 2016;3:17-26. [DOI: 10.1038/ajgsup.2016.17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
14 Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet 2017;56:1513-23. [PMID: 28353055 DOI: 10.1007/s40262-017-0535-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
15 Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2015;21:2948-57. [DOI: 10.1097/mib.0000000000000631] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]